Matrix metalloproteinases and lung cancer

被引：0

作者：

Oguz Soydinc, Hilal ^{[1
]}

Camlica, Hakan ^{[2
]}

Duranyildiz, Derya ^{[3
]}

Kaytan Saglam, Esra ^{[4
]}

Tas, Faruk ^{[5
]}

Yasasever, Vildan ^{[1
]}

Dalay, Nejat ^{[3
]}

机构：

[1] Istanbul Univ, Onkol Enstitusu, Temel Onkol Anabil Dali, Kanser Biyokimyasi Bilim Dali, Istanbul, Turkey

[2] Istanbul Univ, Onkol Enstitusu, Temel Onkol Anabil Dali, Preyantif Onkol Anabilim Dali, Istanbul, Turkey

[3] Istanbul Univ, Onkol Enstitusu, Tercel Onkol Anabilim Dali, Istanbul, Turkey

[4] Istanbul Univ, Tip Fak, Radyasyon Onkol Anabilim Dali, Istanbul, Turkey

[5] Istanbul Univ, Onkol Enstitusu Klin, Onkol Anabilim Dali, Istanbul, Turkey

来源：

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY | 2006年 / 21卷 / 02期

关键词：

Gelatinase B; lung cancer; lung/metabolism/radiation effects; lung neoplasms/blood/enzymology /radiotherapy; Matrix Metalloproteinases; MMP; 9; tissue inhibitor of Metalloproteinase-1;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OBJECTIVES The aim of this study was to determine the pretreatment levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in lung cancer patients. METHODS We investigated the serum MMP-9 and TIMP-1 values in 20 lung cancer patients by ELISA and the results were compared with the controls (n=20). RESULTS MMP-9 (p<0.001) and TIMP-1 (p<0.001) values of patients were significantly higher than the controls. CONCLUSION Our data indicate that detection of serum levels of MMP-9 and TIMP-1 can be used as diagnostic parameters for lung cancer.

引用

页码：53 / 56

页数：4

共 15 条

[1]

[Anonymous], 1997, AM JOINT COMMITTEE C, P127

[2]

Darendeliler E, 1995, AKCIGER KANSERI, P91

[3]

GARBISA S, 1992, CANCER RES, V52, P4548

[4]

Iizasa T, 1999, CLIN CANCER RES, V5, P149

[5] Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment [J].

Jumper, C ;

Cobos, E ;

Lox, C .

RESPIRATORY MEDICINE, 2004, 98 (02) :173-177

[6] Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer [J].

Laack, E ;

Köhler, A ;

Kugler, C ;

Dierlamm, T ;

Knuffmann, C ;

Vohwinkel, G ;

Niestroy, A ;

Dahlmann, N ;

Peters, A ;

Berger, J ;

Fiedler, W ;

Hossfeld, DK .

ANNALS OF ONCOLOGY, 2002, 13 (10) :1550-1557

[7] Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer -: Relation to clinicopathological factors, β-catenin and prognosis [J].

Leinonen, T ;

Pirinen, R ;

Böhm, J ;

Johansson, R ;

Ropponen, K ;

Kosma, VM .

LUNG CANCER, 2006, 51 (03) :313-321

[8] Matrix metalloproteinases in lung diseases [J].

Ohbayashi, H .

CURRENT PROTEIN & PEPTIDE SCIENCE, 2002, 3 (04) :409-421

[9]

Pinto CA, 2003, CLIN CANCER RES, V9, P3098

[10] MULTIPLE-MODES OF ACTIVATION OF LATENT HUMAN FIBROBLAST COLLAGENASE - EVIDENCE FOR THE ROLE OF A CYS-73 ACTIVE-SITE ZINC COMPLEX IN LATENCY AND A CYSTEINE SWITCH MECHANISM FOR ACTIVATION [J].

SPRINGMAN, EB ;

ANGLETON, EL ;

BIRKEDALHANSEN, H ;

VANWART, HE .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (01) :364-368

← 1 2 →